drugset

drugset / Trial / NCT06473961

A Phase Ib Study of GC101 in NSCLC

NCT06473961 ↗

Phase 1 Recruiting 20 enrolled Shanghai Juncell Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.

Timeline

Start: 2024-10-14
Primary completion: 2026-01-01
Completion: 2027-07-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GC101 TIL	Cell therapy	—	—

Indications